Abstract
Modulation of nucleic acid antimetabolite cytotoxicity by preformed purines and pyrimidines may not only complicate the interpretation of drug sensitivity tests and other in vitro studies but also adversely affect treatment in vivo. Previously we reported that in a lymphocyte clonal assay, thymidine and hypoxanthine released from dead or damaged cells reduced methotrexate cytotoxicity. We now report that the nucleoside transport inhibitor dipyridamole (DP), at 1.0 microM, abolished 3H-thymidine uptake into PHA stimulated lymphocytes, potentiated methotrexate cytotoxicity and reversed modulation of methotrexate cytotoxicity by exogenous thymidine and hypoxanthine. Normal growth of lymphocytes at high density was unaffected by 1.0-5.0 microM dipyridamole, while growth at low densities was only slightly reduced. Hydroxy-nitrobenzylthioguanosine (555) was a less potent inhibitor of 3H-thymidine uptake and was toxic to normal lymphocytes at concentrations inhibiting 3H-thymidine uptake. Nucleoside transport inhibitors isolate the cellular effects of nucleic acid antimetabolites, and provide a tool to study mechanisms of antifolate cytotoxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hughes, J., Tattersall, M. Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport. Br J Cancer 59, 381–384 (1989). https://doi.org/10.1038/bjc.1989.76
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.76
This article is cited by
-
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs
Cancer Chemotherapy and Pharmacology (1995)